MOUNT PLEASANT, Mich., Nov. 10 /PRNewswire/ -- Dendritic Nanotechnologies
Inc. (DNT), a company focused on the discovery, development, and
commercialization of dendrimer technologies to create a new generation of
innovative products for the identification and treatment of human diseases,
and Lumera have entered into a joint research agreement to co-develop certain
proprietary surface chemistries suitable for specific applications of Lumera's
label-free array reader, ProteomicProcessor(TM).
Under the terms of this agreement, DNT will build chemistries on
proprietary Lumera surfaces, focusing efforts on using their expertise and
patent holdings in the area of dendrimers. Lumera will use their proprietary
instrument designs and biological systems to test and evaluate the
dendrimer-based approaches. It is expected that the combined expertise of
Lumera in optically active polymers, defined surfaces and label-free detection
systems, and the dendrimer expertise of Dendritic Nanotechnologies, will
result in unique performance features and benefits for proteomic applications.
Terms of the agreement were not disclosed.
"This research agreement with Lumera is an important milestone for DNT
since it represents one of the first commercial applications of our recently
announced Priostar dendrimers," said Robert Berry, DNT's chief executive
DNT's new dendrimer technology is called Priostar(TM) and offers a
significant advantage over other precision nanostructures by reducing the
complexity and duration of the synthesis process. The new Priostar family of
scalable, precision dendrimers breaks through previous cost barriers and
addresses industry needs for nanostructures that can be manufactured in high
volumes at costs attractive for a wide variety of uses.
Lumera is an emerging leader in the field of nanotechnology. The company
designs proprietary molecular structures and polymer compounds for the
bioscience and communications/computing industries, both of which represent
large market opportunities. The company also has developed proprietary
processes for fabricating such devices. For more information, please visit
Dendritic Nanotechnologies Inc. (DNT) is focused on the discovery,
development, and commercialization of dendrimer technologies to create a new
generation of innovative products for the identification and treatment of
human diseases. DNT's proprietary dendrimer platform serves as a targeted
diagnostic and therapeutic delivery system for a wide variety of drugs to
cancer cells and other diseases. Improved efficacy, enhanced solubility, and
lower toxicity have been demonstrated for many existing drugs. DNT is
committed to producing commercially viable dendrimers that can be manufactured
in large quantities, and to driving down manufacturing complexity and costs.
The company has a patent pending on its Priostar(TM) family of dendrimers, a
novel dendrimer family that breaks through previous cost and manufacturing
SOURCE Dendritic Nanotechnologies Inc.